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Abstract
Objectives: The objective of this article is to discuss the rationale/
background for early intervention in bipolar disorder. Method: Narrative 
review. Results: There are often significant delays before the diagnosis of 
bipolar disorder is made and effective management initiated. Growing 
evidence from both preclinical and clinical literature points to a clear 
need for improved early identification and early intervention in bipolar 
disorder. Increasing efforts are being applied to the identification of those 
at high risk of onset of bipolar disorder. It is hoped that identification of 
an early prodrome of illness will allow preventative measures to be taken. 
Conclusions: There is a clear rationale for improved early identification 
and early intervention in bipolar disorder.
Descriptors: Bipolar disorder; Early intervention; Review; Determination; 
Treatment outcome  
Resumo
Objetivos: O objetivo do artigo é discutir os fundamentos para a intervenção 
precoce no transtorno bipolar. Método: Revisão narrativa. Resultados: 
Frequentemente existe um atraso significativo com relação ao momento em que 
o transtorno bipolar é detectado e o início do tratamento. Evidências crescentes 
oriundas de estudos pré-clínicos e clínicos apontam para a clara necessidade 
de melhorar a detecção e o tratamento precoces no transtorno bipolar. Esforços 
também tem sido direcionados para a identificação de indivíduos em alto 
risco. Espera-se que a identificação do pródromo do transtorno bipolar 
permita a instauração de medidas preventivas. Conclusões: Existem bases 
claras para o investimento na melhora da detecção e tratamento precoces do 
transtorno bipolar.
Descritores: Transtorno bipolar; Intervenção precoce; Revisão; Determinação; 
Resultado de tratamento
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Introduction
Bipolar disorder (BD) is a major global health problem that 
leads to significant lifetime morbidity and mortality. While the 
onset of illness is typically in youth, there are often significant 
delays before the diagnosis is made and effective management 
initiated. Growing evidence from both preclinical and clinical 
literature points to the clear imperative for improved early 
identification and early intervention in BD. In addition to 
this evidence in established BD, increasing efforts are being 
applied to the identification of those at high risk of onset of 
BD. Drawing from the success of such an approach in non-
affective psychosis, it is hoped that identification of an early 
prodrome of illness will allow preventative measures to be 
taken. Here we draw together the current evidence in these 
areas.
BD remains a clinical diagnosis. The two major diagnostic 
classification systems worldwide are the International Classification 
of Diseases, 10th edition (ICD-10) and the Diagnostic and 
Statistical Manual of the American Psychiatric Association, 4th 
edition (DSM-IV). In both systems, BD is characterized by 
episodes of mood disorder. The key feature differentiating BD 
from recurrent depressive disorders (major or unipolar depression) 
is the lifetime presence of mania or hypomania or mixed episodes. 
DSM-IV further distinguishes between bipolar I disorder, where 
mania is observed, and bipolar II disorder, where hypomania is 
observed alongside one or more episodes of major depression. The 
classification is expected to undergo at least some changes with 
the forthcoming fifth edition of DSM.
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Global impact
BD has a worldwide distribution. Clinical samples are 
likely to underestimate prevalence; the most accurate 
available estimates come from painstaking epidemiological 
household surveys. The recent National Comorbidity Survey 
- Replication (NCS-R)1 obtained data from 9282 English-
speaking adults across the continental USA, finding lifetime 
prevalence estimates of 1% for bipolar I and 1.1% for bipolar 
II, with a further 2.4% having subthreshold BD. Similar 
estimates were obtained by the World Mental Health Survey 
Initiative2, in which face-to-face interviews of 61392 adults 
across 11 countries in the Americas, Europe, and Asia were 
performed. Lifetime prevalences were 0.6% for bipolar I, 0.4% 
for bipolar II, 1.4% for subthreshold BD, and 2.4% for the 
bipolar spectrum. A large proportion of those surveyed had 
severe symptoms and role impairment confirming the serious 
impact of the disorder.
BD is associated with increased mortality. A number of large 
studies of people admitted to hospitals with BD have found 
elevated mortality. In a study of over 15000 patients in Sweden, 
standardized mortality ratios (SMR) in BD for death by suicide 
were 15.0 for males and 22.4 for females, and for natural causes 
of death SMRs were also significantly elevated, with most excess 
deaths from natural causes3. Similar findings were observed in 
Denmark4. Interestingly, in a community sample, identifying 
all patients with a first presentation of bipolar I, not restricted 
to those admitted to hospital, an elevated risk of suicide was 
also described (SMR 9·77, 95% confidence interval [CI] 
4·22–19·24), but no significant increase in deaths by other causes 
was observed5. An elevated risk of suicidality is not restricted to 
those with bipolar I disorder. In a meta-analysis of 15 studies, 
rates of attempted suicide did not differ between bipolar I and 
bipolar II disorder6. 
Early Onset
The onset of illness in BD is often in young adulthood. In 
an international study of 1566 patients across six sites using 
modern diagnostic criteria, the median age of onset for bipolar 
I was 24.3 years, and for bipolar II 30.17. There is some 
evidence that age of onset characterizes different subgroups 
of BD patients. In a recent UK study of more than 1000 
participants with bipolar I disorder, three distributions were 
observed; one group with mean onset age of 18.9, another 
with mean onset age of 28.3, and a third group with mean 
onset age of 43.3 years8. The group with the earliest onset was 
found to have a stronger family history of mood disorders, 
and also some markers of greater clinical severity such as 
greater suicidality, more rapid-cycling, more episodes of mania 
and depression, and greater scores on lifetime measures of 
depressive symptoms.
BD can be rapidly recurrent even after a first episode. In a 
US study of 166 people followed up for two years after their 
first episode of mania, 40% went on to experience a new 
episode of mania or depression, and 19% switched phases 
of illness without recovery9. Similarly, in a Canadian study 
of 53 participants with first episode mania, more than half 
experienced a new mood episode within the first year of 
follow-up10, and earlier age of onset significantly predicted 
increased recurrence.
Polarity of initial episode appears to play a role in 
predicting future illness course. In a follow-up of 303 first 
episode patients from Europe and the US over two years11, 
first episode polarity strongly predicted the preponderance 
of future illness. Similarly, a UK study of 553 participants 
with well characterized bipolar I disorder found that an 
initial depressive episode at onset was associated with a 
predominantly depressive polarity and more frequent and 
more severe depressive episodes12.
Delayed diagnosis
Diagnosis of BD appears to be commonly delayed in routine 
practice. An average delay of 10 years between first symptoms 
and first treatment was reported in a well-characterized 
international outpatient sample13. Similar delays were 
described by support group participants in the US diagnosed 
with BD, of whom one third reported having waited 10 years 
or more before accurate diagnosis14. In a retrospective study of 
over 200 people in Australia, while their symptoms on average 
had initially started by the age of 18, and medical treatment 
been sought at 24 years old, the median age at diagnosis was 
30 years15. The most common previous diagnosis in both these 
samples was of unipolar depression.
A delayed diagnosis may have a range of adverse effects. In 
studies of outpatients with BD, increased delay in diagnosis 
and initiation of appropriate treatment has been associated 
with increased severity of depression16,17, decreased quality 
of life16 and greater likelihood of attempted suicide18. 
Unsurprisingly, given these clinical adverse effects, healthcare 
costs have also been found to increase with each month of 
delayed diagnosis of BD19.
Diagnostic error
In the early stages of BD, two key causes of diagnostic error 
can be differentiation from major depressive disorder or other 
psychotic illness. The differentiation of BD from unipolar 
depression represents a common clinical challenge. As it 
becomes clearer that the optimal management of bipolar and 
unipolar depression differs, with conventional antidepressants 
showing disappointing efficacy in recent studies and carrying 
risks of increased mood instability, the importance of making 
this distinction becomes greater. Inevitably, some people who 
experience only depressive episodes early in the course of their 
illness will ‘convert’ to bipolar on experiencing their first 
episode of hypomania or mania. A number of attempts have 
been made to differentiate episodes of bipolar and unipolar 
depression on the basis of observed symptoms.
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A recent synthesis noted that ‘atypical’ features such as 
hypersomnia, hyperphagia, and leaden paralysis, psychomotor 
retardation, psychotic features, pathological guilt, and lability 
of mood were more common in bipolar depression20. Bipolar 
depression was also associated with an earlier age of onset of 
first depressive episode, more prior episodes of depression, 
shorter depressive episodes, and a family history of BD. A 
prospective validation of this ‘probabilistic’ approach has 
yielded promising results21. Another recent comparison of 
symptom features between large numbers of people with 
unipolar and bipolar illness similarly linked the presence of 
psychosis, diurnal mood variation and hypersomnia during 
depressive episodes, and a greater number of shorter depressive 
episodes, with bipolar diagnosis22. There are thus emerging 
pointers towards the possibility of identifying those with a 
higher risk of a bipolar illness even before mood elevation is 
experienced.
Some people who have already experienced hypomania or 
mania are mistakenly diagnosed with recurrent depressive 
disorder. This may be made more likely since hypomanic 
symptoms may not necessarily be identified as pathological 
by the patient, and may thus not be spontaneously reported. 
Screening tools such as the Hypomania Checklist (HCL-32)23 
and Bipolar Spectrum Diagnostic Scale (BSDS)24 may be of 
benefit, although symptoms identified may not reach current 
diagnostic thresholds for BD25.
Increasing interest is attached to the presence of ‘subthreshold’ 
bipolarity in people currently diagnosed with major depression, 
such as might be identified by these screening instruments. 
This has the potential to greatly expand the boundaries of 
BD. In a 20-year prospective community cohort study of 
young adults, it was found that a broad definition of bipolar 
II disorder gives a cumulative prevalence rate of 10.9%, 
compared to 11.4% for broadly defined major depression26. 
Using current classifications, the prevalence of BD is lower 
than that of unipolar depression; for example, in the NCS-R 
study the lifetime prevalence of major depressive disorder was 
16.6%, whereas for bipolar I and II it was 3.9%27. However, 
nearly 40% of study participants with a history of major 
depressive disorder had a history of subthreshold hypomania28. 
This more bipolar’ subgroup had a younger age at onset, more 
episodes of depression, and higher rates of comorbidity than 
those without a history of hypomania, which suggests that the 
difference may come to be of clinical significance.
A proportion of people presenting with a first episode of 
apparently non-affective psychosis will go on to be ultimately 
diagnosed with BD. Psychotic features are not uncommon 
during mania. In the McLean-Harvard First-Episode Mania 
Study, studying people during a first manic/mixed episode 
of bipolar I disorder, most subjects (88.6%) had some initial 
psychotic features9. In the McLean-Harvard International 
First Episode Project, patients hospitalized in a first psychotic 
episode were assessed by standard criteria at baseline and at 
24 months29. Of 500 participants completing the study, the 
authors found that initial diagnoses of bipolar I disorder 
remained stable in 96.5% of cases. However, over one quarter 
of changes in diagnosis were from another psychotic illness 
at baseline to bipolar I disorder after two years. It is therefore 
important to be alert for the development of BD in people 
with early psychosis.
Comorbidity
Comorbidity is common in BD. In the World Mental Health 
Survey Initiative, three quarters of patients had at least one 
comorbidity, commonly anxiety disorders and substance/
alcohol abuse2. Follow-up of a cohort of 591 individuals (292 
men and 299 women) in Zurich, Switzerland, who received 
six waves of diagnostic interviews over a 20-year period30, 
allowed for clarification of the chronology of that comorbidity. 
Participants with manic symptoms were found to be at elevated 
risk for the later onset of problems with alcohol, cannabis 
and benzodiazepines. Bipolar II disorder predicted problems 
with alcohol and benzodiazepines. By contrast, there is some 
evidence that anxiety disorders tend to precede the onset of 
BD31.
Personality disorder can also pose an important comorbidity32. 
The emotional instability of borderline personality disorder 
can lead to its being viewed as a differential diagnosis of BD, 
or delay recognition of bipolar comorbidity. In clinical practice 
many patients with borderline personality disorder also meet 
diagnostic criteria for BD33. 
Illness progression
There is increasing evidence pointing to disease progression 
over time. Almost one century ago, Kraepelin noted that 
people with BD presented a progressively worse clinical course 
over time, with a shortening of inter-episodic periods34. Strong 
evidence now confirms that recurrence rates increase with 
further episodes of illness35-37. This effect persists even when 
adjustments are made for individual differences in frailty 
toward recurrence.
There is evidence from cross-sectional studies that a 
worse prior course of illness is associated with greater 
neuropsychological dysfunction38.  Even early in illness, 
impaired cognitive functioning has a major impact in 
functional outcome39. Consistent with this, with a greater 
number of episodes of illness requiring hospital admission 
comes a greater degree of sustained functional impairment, 
even in euthymic patients40.
There is evidence that progression may increase the risk 
of treatment resistance. In an analysis of multiple trials of 
olanzapine in the treatment of BD, it was found that those 
in the earlier stages of illness had a more favorable response 
to treatment41. A similar effect has also been reported for 
response to lithium, although this is not consistent across all 
studies42. A potential increase in treatment non-response is not 
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restricted to pharmacological management. In a meta-analysis 
of psychological interventions to prevent relapse in BD, it 
appeared that the psychological therapies were less effective 
in those with a high number of previous episodes43.
A substantial body of neuroimaging evidence now 
demonstrates abnormalities in brain structure in BD. For 
example, a major meta-analysis demonstrated enlargement 
of the lateral ventricles and increased rates of deep white 
matter hyper intensities in BD44. More recently, an analysis 
of individual patient data combined across eleven research 
groups demonstrated a reduction in overall cerebral volume 
with increased illness duration45. This reduction in cerebral 
volume with longer duration of illness is consistent with a 
neurodegenerative process in the pathophysiology of BD.
How can this disease progression be understood? Post 
and collaborators proposed the ‘kindling model’, in which 
parallels were drawn between observations in the experimental 
induction of seizures, illness progression, and drug tolerance in 
affective disorders such as BD46,47. These clinical observations 
could be understood as reflecting long-term changes in gene 
expression and downstream consequences altering a balance 
between pathological and compensatory systems. More 
recently, Kapczinski and collaborators developed the idea of 
‘allostatic load’, where the genetic background interacts with 
an accumulating burden of biological ‘wear and tear’ due to 
different environmental stressors and the effects of illness 
episodes themselves48. It appears that disease progression may 
reflect an interaction of multiple processes49. These may not 
be restricted to changes in neurotransmitter systems, but may 
include changes in inflammatory cytokines and neurotrophins, 
such as BDNF50, and mitochondrial dysfunction51 with 
increased oxidative stress52. Importantly, the convergence of 
preclinical and clinical data point to a key role for early and 
sustained preventative measures, not only to avoid episodes 
of illness itself, but also potentially to prevent the associated 
accumulation of neurobiological vulnerability factors.
Management
Comprehensive guidance on the management of BD is 
beyond the scope of this article and can be found elsewhere53. 
The major clinical problems can be considered the treatment of 
acute episodes of bipolar depression, manic or mixed episodes, 
and the prevention of relapse. Appropriate pharmacological 
management is a mainstay of effective treatment, although 
it is important to recognize that pharmacological agents 
need to be delivered as part of a coherent package of care 
that may also involve specific psychological therapies54 and 
other psychological and social support.  For example, there 
is evidence that effective treatment of substance misuse 
comorbidity can improve both adherence and outcomes. In the 
STEP-BD study, patients with BD who experience sustained 
remission from substance use disorders fared better than 
patients with ongoing substance use disorders, but not as well 
as subjects with no history of substance-related problems55.
Recent years have yielded a much improved evidence base to 
guide general management. On the one hand, the increasing 
availability of systematic reviews and meta-analyses allows 
the existing literature to be better understood. Furthermore, 
independent, high quality, randomized controlled trials have 
begun to provide answers to some of the important clinical 
questions in the management of acute episodes of illness56,57 
and prevention of relapse58. Key recent findings include 
increasing evidence that bipolar depression may require rather 
different management than unipolar depression59. Future 
studies could investigate whether the presence of predictors 
of bipolarity in unipolar depression warrants differential 
management, even if full diagnostic criteria for BD are not 
met. Remission from depressive symptoms is an important 
treatment aim, since even subsyndromal depressive symptoms 
are associated with functional impairment and disability60. 
Preventative treatment is recognized as increasingly 
important. Traditionally, particularly in European guidelines, 
prophylactic medication has often been reserved for cases 
where multiple episodes of illness occur in rapid succession61, 
however, a case can be made for considering preventative 
medication after a single severe manic episode53.
As noted above, there is a growing theoretical rationale for 
early prevention. Some initial data suggest that lithium may 
play a neuroprotective role, preventing structural changes in 
hippocampus and amygdala45. There is also concrete clinical 
evidence of substantial benefits on major outcomes. Data from 
controlled trials indicate that people with BD randomized 
to receive lithium treatment have both decreased suicide 
rates and all-cause mortality62. Psychological interventions 
have an important role as an adjunct to pharmacological 
management63, with effects that appear to be sustained well 
after the course of therapy.
Specialized early intervention services
There remains uncertainty around whether there are specific 
differences in appropriate treatment models for the earliest 
stages of BD. The lesson of early intervention services for 
psychosis has been that they can offer substantial benefits 
including significant positive effects on psychotic and negative 
symptoms, secondary substance abuse, treatment adherence, 
and a higher satisfaction with treatment64. It appears that 
early treatment of psychosis allows for the use of lower doses 
of antipsychotic medication65. Multicenter randomized trials 
are underway to investigate whether similar specialized care 
in the early stages of severe affective disorders proves superior 
to treatment as usual66.
Identifying at-risk individuals
Building on the clinical and neurobiological evidence 
of disease progression outlined above, staging models are 
beginning to be developed67. Similarly to the approach taken 
for some general medical conditions, an effective staging 
model could provide a structure for assessment and most 
Art05_Ingl.indd   200 12/20/11   4:43 PM
Taylor M et al.
S201 • Revista Brasileira de Psiquiatria • vol 33 • Supl II • out2011 
appropriately direct therapeutic efforts. These might include 
people in a prodrome to the onset of BD proper to whom 
preventative measures could be offered.
Can a prodromal period be clinically defined? A number 
of studies, both retrospective and prospective, have aimed 
to identify features of this period68. Taken together, these 
studies indicate that symptoms can predate the onset of BD 
proper by months to years and can be attenuated forms of 
bipolar symptoms, general symptoms common to a range of 
mental disorders, and personality traits, such as cyclothymia. 
However, none of these features show high sensitivity for 
progression to BD. Another recent review concluded that the 
specificity of prodromal symptoms and signs appears to be 
low69. It has been noted that a bipolar prodrome may in some 
cases be indistinguishable from the schizophrenia prodrome 
based on clinical and neurocognitive measures currently used 
in high-risk schizophrenia programs70. Thus, clinical features 
alone may not prove sufficient for all cases. 
Genetics play a major role in BD71. Estimates of heritability 
from twin studies place it at over 80%72,73, and there is also a 
gradation of risk of mood disorder according to the degree of 
genetic relatedness74. Family history is thus a strong putative 
method for identifying people at elevated risk of developing 
BD. Observational studies found that the offspring of bipolar 
parents shows a high risk for psychiatric disorders, and 
specifically for early-onset bipolar spectrum disorders75-77.
A number of ongoing studies aiming to prevent conversion 
to BD combine family history with the presence of (non-
specific) symptoms to identify a high risk group for 
intervention. A recent Melbourne study identified at-risk 
groups by the presence of subthreshold mania, depression with 
cyclothymia, or depression together with having a first degree 
relative with BD78. These criteria showed some initial success 
in identifying people who would progress to a BD diagnosis. 
Specific intervention may prove valid for such groups. High 
rates of response have been reported in uncontrolled studies 
of young people with symptoms and a positive family history 
of BD for both valproate79 and quetiapine80. A version of 
family-focused treatment adapted for youth at high risk for 
BD (FFT-HR) has also been developed, with promising initial 
results in a similar group with active mood symptoms and a 
positive parental history81.
Conclusions
Growing evidence points to the clear clinical imperative 
for improved early identification and early intervention in 
BD. In particular, preclinical and clinical evidence points to 
the importance of early and sustained treatment for relapse 
prevention. In addition to this evidence in established BD, 
increasing efforts are being applied to the identification of 
those at high risk of onset of BD. Drawing from the success of 
such an approach in non-affective psychosis, it is hoped that 
the identification of an early prodrome of illness will allow 
preventative measures to be taken.
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